NHS AI Blood Test May Reduce Invasive Cancer Screenings for Women

Key Takeaways

A new AI blood test could prevent thousands of invasive procedures for women suspected of having womb cancer.
The PinPoint blood test, developed through a collaboration with Leeds Teaching Hospitals NHS Trust, achieved a 99% accuracy rate in identifying and ruling out gynaecological cancers.
By targeting low-risk patients, the test aims to ease patient discomfort and reduce pressure on NHS services.

AI Blood Test Revolutionizes Womb Cancer Diagnosis

Thousands of women in England could bypass invasive diagnostic procedures for suspected womb cancer, thanks to a new AI blood test called PinPoint, designed to identify low-risk patients. The trial, conducted by Leeds-based PinPoint Data Science, engaged 16,481 patients referred by GPs across 170 practices in Yorkshire.

Each year, approximately 90,000 postmenopausal women are referred for investigations after experiencing postmenopausal bleeding, a common symptom of womb cancer (endometrial cancer). Out of this group, about 10,000 are diagnosed with the disease. Traditionally, NHS pathways mandate that all referred women undergo a transvaginal ultrasound scan, with many needing additional invasive procedures like hysteroscopy and biopsy.

The PinPoint test presents a significant shift in this protocol. By leveraging machine learning to analyze 30 blood biomarkers, the test categorizes patients into low, elevated, or high-risk groups for cancer. Notably, it could allow around one in five women—approximately 18,000 patients each year—to avoid unnecessary invasive procedures, as it effectively rules out those at very low risk.

Professor Sean Duffy, chief medical officer at PinPoint Data Science and a former NHS England national clinical director for cancer, hailed the results as “remarkable by any clinical standards.” He emphasized the test’s ability to safely exclude low-risk women, potentially sparing thousands from uncomfortable procedures.

The trial demonstrated the test’s impressive 99% accuracy rate in both identifying and ruling out gynaecological cancers, outperforming current conventional diagnostic methods. Mid Yorkshire Teaching NHS Trust plans to use the technology for six gynaecological cancers, while Leeds Teaching Hospitals NHS Trust will focus on suspected gynaecological cancer referrals in its initial rollout.

Consultant gynaecologist Tracy Jackson, cancer unit lead at Leeds Teaching Hospitals NHS Trust, pointed out that the majority of women referred do not have cancer, highlighting that traditional investigations can be uncomfortable and distressing. The introduction of the blood test in primary care could reduce unnecessary procedures, lower waiting times, and facilitate quicker diagnoses and treatments for women actually diagnosed with cancer.

Samantha Harrison from Cancer Research UK reinforced the test’s potential, stating, “Spotting cancer early saves lives.” She acknowledged that while more research is needed to fully assess the benefits for patients and the NHS, initial study results are promising, indicating the test could serve as a straightforward method for ruling out endometrial cancer through a simple blood draw, without the need for further invasive testing.

The content above is a summary. For more details, see the source article.